NEW YORK (360Dx) – Antimicrobial resistance shot into the frontline of diagnostic testing in 2018 with a slew of regulatory approvals to bring new technologies to the market while diagnostic developers continued with their efforts to improve on existing methods.

Throughout the year, the US Food and Drug Administration cleared new tests used to help manage microbial resistance while companies pushed their technologies toward commercialization, and other industry players struck deals to commercialize their products and increase their adoption.